We discuss recent insight that helps to understand the contrasting effects of TGFβ signalling and ROS on early stages of tumour growth versus the metastatic processes, and how these discoveries impact therapeutic strategies for targeting ROS and TGFβ signalling in PDAC. Here, TGFB1 is linked to neoplasm.